Mirati Therapeutics, Inc. (MRTX) Reaches $4.22 After 6.00% Up Move, BB&T (BBT) Had 9 Bullish Analysts

July 17, 2017 - By wolcottdaily

Among 24 analysts covering BB&T Corp (NYSE:BBT), 9 have Buy rating, 2 Sell and 13 Hold. Therefore 38% are positive. BB&T Corp had 49 analyst reports since July 17, 2015 according to SRatingsIntel. The stock of BB&T Corporation (NYSE:BBT) has “Neutral” rating given on Wednesday, January 11 by UBS. The stock has “Hold” rating by Oppenheimer on Wednesday, August 19. The stock of BB&T Corporation (NYSE:BBT) has “Outperform” rating given on Thursday, April 7 by Raymond James. The rating was upgraded by SunTrust to “Outperform” on Monday, May 16. The firm earned “Underweight” rating on Monday, November 14 by Morgan Stanley. The firm earned “Neutral” rating on Monday, January 9 by Piper Jaffray. The firm earned “Buy” rating on Wednesday, April 5 by RBC Capital Markets. On Friday, October 16 the stock rating was downgraded by Hilliard Lyons to “Neutral”. The stock has “Equal Weight” rating by Barclays Capital on Tuesday, January 3. The company was maintained on Tuesday, June 27 by Keefe Bruyette & Woods. See BB&T Corporation (NYSE:BBT) latest ratings:

28/06/2017 Broker: BMO Capital Markets Rating: Hold New Target: $48.0000 Maintain
27/06/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $46.0000 Maintain
22/06/2017 Broker: RBC Capital Markets Rating: Buy New Target: $50.0000 Maintain
08/06/2017 Broker: Jefferies Rating: Hold New Target: $49.0000 Maintain
26/05/2017 Broker: BMO Capital Markets Rating: Hold New Target: $48.0000 Maintain
26/05/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $46.0000 Maintain
24/04/2017 Broker: FBR Capital Rating: Hold Maintain
05/04/2017 Broker: RBC Capital Markets Rating: Buy New Target: $50.00 Maintain
23/01/2017 Broker: Hilliard Lyons Old Rating: Neutral New Rating: Buy Upgrade
19/01/2017 Broker: FBR Capital Rating: Mkt Perform Old Target: $50 New Target: $49 Maintain

The stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) is a huge mover today! About 190,641 shares traded. Mirati Therapeutics, Inc. (NASDAQ:MRTX) has declined 76.51% since July 17, 2016 and is downtrending. It has underperformed by 93.21% the S&P500.The move comes after 7 months positive chart setup for the $97.27 million company. It was reported on Jul, 17 by Barchart.com. We have $4.47 PT which if reached, will make NASDAQ:MRTX worth $5.84M more.

About 1.00 million shares traded. BB&T Corporation (NYSE:BBT) has risen 20.68% since July 17, 2016 and is uptrending. It has outperformed by 3.98% the S&P500.

BB&T Corporation is a financial holding company. The company has market cap of $35.87 billion. The Firm conducts its business primarily through its bank subsidiary, Branch Banking and Trust Company , and other nonbank subsidiaries. It has a 17.53 P/E ratio. The Company’s divisions include Community Banking, Residential Mortgage Banking, Dealer Financial Services, Specialized Lending, Insurance Holdings and Financial Services.

Since January 23, 2017, it had 0 buys, and 22 selling transactions for $56.44 million activity. $6.00M worth of BB&T Corporation (NYSE:BBT) shares were sold by Goodrich Donna C. 39,079 shares were sold by Yates William Rufus, worth $1.77M. $187,483 worth of BB&T Corporation (NYSE:BBT) was sold by Powell Cynthia B on Thursday, March 2. Boyer K. David Jr. also sold $124,426 worth of BB&T Corporation (NYSE:BBT) on Wednesday, March 1. 92,793 shares were sold by Starnes Clarke R III, worth $4.21 million on Monday, January 23. Standridge Brantley J had sold 25,626 shares worth $1.19 million on Wednesday, January 25. On Wednesday, March 8 PATTON CHARLES A sold $481,508 worth of BB&T Corporation (NYSE:BBT) or 10,000 shares.

Investors sentiment decreased to 1.17 in Q4 2016. Its down 0.18, from 1.35 in 2016Q3. It is negative, as 47 investors sold BB&T Corporation shares while 271 reduced holdings. 109 funds opened positions while 262 raised stakes. 518.52 million shares or 2.79% more from 504.45 million shares in 2016Q3 were reported. Creative Planning, Kansas-based fund reported 103,537 shares. Wills Fincl Gp accumulated 0.63% or 16,349 shares. The Florida-based Lba Wealth Management Limited Liability Corp has invested 0.03% in BB&T Corporation (NYSE:BBT). Edgemoor Invest Advsr accumulated 0.09% or 12,220 shares. Calvert Inv Mngmt owns 0.1% invested in BB&T Corporation (NYSE:BBT) for 55,224 shares. Laurion Capital Mgmt Limited Partnership accumulated 106,357 shares. International Sarl owns 22,400 shares. Argyle Mngmt Inc stated it has 51,300 shares. Hartford Investment Mngmt owns 0.2% invested in BB&T Corporation (NYSE:BBT) for 229,977 shares. Meiji Yasuda Asset Management Com Ltd has 10,772 shares. Assetmark has 4,126 shares. Washington Com invested 0.31% in BB&T Corporation (NYSE:BBT). Orrstown Fin Service owns 7,336 shares. 40,982 are owned by Rafferty Asset Ltd Llc. The Michigan-based State Treasurer State Of Michigan has invested 0.1% in BB&T Corporation (NYSE:BBT).

Investors sentiment decreased to 0.81 in 2016 Q4. Its down 0.23, from 1.04 in 2016Q3. It dived, as 12 investors sold Mirati Therapeutics, Inc. shares while 19 reduced holdings. 7 funds opened positions while 18 raised stakes. 9.10 million shares or 3.41% less from 9.42 million shares in 2016Q3 were reported. Blackrock Limited Liability stated it has 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Ghost Tree Capital Limited Co holds 0.2% or 172,184 shares in its portfolio. National Bank Of Ny Mellon has invested 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Northern owns 141,665 shares or 0% of their US portfolio. Susquehanna International Gp Llp has 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Royal Bank & Trust Of Canada owns 855 shares. Rhumbline Advisers holds 0% or 11,629 shares in its portfolio. Macquarie Group Inc holds 80,000 shares or 0% of its portfolio. The Sweden-based Rhenman And Prtn Asset Mgmt Ab has invested 0.05% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). California State Teachers Retirement Sys holds 0% or 26,094 shares in its portfolio. Trexquant L P has 0.02% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Sphera Funds stated it has 0.1% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Millennium Mngmt Limited Liability Company has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Jpmorgan Chase reported 54,261 shares stake. Bnp Paribas Arbitrage has invested 0% of its portfolio in Mirati Therapeutics, Inc. (NASDAQ:MRTX).

Since January 18, 2017, it had 2 insider purchases, and 0 selling transactions for $676,901 activity. $414,573 worth of Mirati Therapeutics, Inc. (NASDAQ:MRTX) was bought by Braslyn Ltd..

Analysts await Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report earnings on August, 3. They expect $-0.81 EPS, up 27.03% or $0.30 from last year’s $-1.11 per share. After $-0.73 actual EPS reported by Mirati Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 10.96% negative EPS growth.

Among 8 analysts covering Mirati Therapeutics (NASDAQ:MRTX), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Mirati Therapeutics had 16 analyst reports since September 17, 2015 according to SRatingsIntel. The firm has “Overweight” rating given on Monday, June 6 by Barclays Capital. Leerink Swann downgraded Mirati Therapeutics, Inc. (NASDAQ:MRTX) on Monday, June 6 to “Mkt Perform” rating. Jefferies maintained Mirati Therapeutics, Inc. (NASDAQ:MRTX) on Monday, June 12 with “Hold” rating. The rating was upgraded by Avondale on Friday, May 6 to “Market Outperform”. As per Monday, June 6, the company rating was downgraded by Jefferies. The stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) has “Overweight” rating given on Monday, October 19 by Barclays Capital. The stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) earned “Buy” rating by Citigroup on Wednesday, January 13. The stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) has “Neutral” rating given on Monday, November 23 by Citigroup. The firm has “Buy” rating given on Monday, June 6 by Citigroup. The firm has “Outperform” rating by Wedbush given on Tuesday, May 24.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: